Cross-source evidence timeline

Vasopressin research timeline

Follow 83 selected, directly cited source records from September 25, 1998 through November 5, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

83Selected records
17Source years
3Evidence lanes
November 5, 2026Latest source date

Source year

2026

32 records
  1. Literature metadata

    Oxytocin, vasopressin, and their crosstalk in sexually-dimorphic psychiatric conditions.↗

    PubMed lists PMID 41862144 in Neuroscience and biobehavioral reviews as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance).↗

    PubMed lists PMID 39438674 in Nature reviews. Nephrology as Journal Article, Review, Consensus Statement, with publication-date metadata of 2024-10-22 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT05958342↗

    PeptideScanner retained ClinicalTrials.gov record NCT05958342 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04501861↗

    PeptideScanner retained ClinicalTrials.gov record NCT04501861 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT07633600↗

    PeptideScanner retained ClinicalTrials.gov record NCT07633600 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  6. Literature metadata

    Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants.↗

    PubMed lists PMID 40602377 in Hormone research in paediatrics as Journal Article, Review, with publication-date metadata of 2025-07-02 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    A Scoping Review on Salivary Oxytocin and Vasopressin Measurement in the Dog.↗

    PubMed lists PMID 40867749 in Animals : an open access journal from MDPI as Journal Article, Review, with publication-date metadata of 2025-08-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Arginine vasopressin deficiency: towards a better characterization.↗

    PubMed lists PMID 42677919 in Endocrine-related cancer as Journal Article, Review, with publication-date metadata of 2026-09-01 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    The vasopressin system as an immunoneuroendocrine therapeutic target in inflammatory conditions.↗

    PubMed lists PMID 42647984 in Current opinion in pharmacology as Journal Article, Review, with publication-date metadata of 2026-08-10 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT06709573↗

    PeptideScanner retained ClinicalTrials.gov record NCT06709573 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  11. Literature metadata

    From cranial diabetes insipidus to vasopressin deficiency: terminology, tests and treatment.↗

    PubMed lists PMID 41667271 in Archives of disease in childhood as Journal Article, Review, Case Reports, with publication-date metadata of 2026-08-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Important Role of Renin-Angiotensin System and Vasopressin System in Cardiovascular, Metabolic and Psychogenic Disorders in Pregnancy and Early Postnatal Life: A Narrative Review.↗

    PubMed lists PMID 42653310 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2026-08-16 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  13. Literature metadata

    Pharmacological mechanisms and clinical evidence of vasopressin, steroids, and epinephrine triple therapy in in-hospital cardiac arrest.↗

    PubMed lists PMID 42609684 in Frontiers in cardiovascular medicine as Journal Article, Review, with publication-date metadata of 2026-08-03 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  14. Literature metadata

    Arginine Vasopressin Deficiency and Oxytocin Deficiency in the Endocrine Clinic.↗

    PubMed lists PMID 41363127 in The Journal of clinical endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2026-03-17 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  15. Literature metadata

    Vasopressin 1a Receptor Antagonists for Pathological Aggression in Neurodegenerative and Other CNS Diseases.↗

    PubMed lists PMID 42072430 in Biomedicines as Journal Article, Review, with publication-date metadata of 2026-04-14 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  16. Literature metadata

    Vasopressin Versus Norepinephrine As First-Line Vasopressor Therapy for Vasoplegic Shock Following Cardiac Surgery: A Systematic Review.↗

    PubMed lists PMID 42583609 in Cureus as Journal Article, Review, with publication-date metadata of 2026-07-12 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  17. Clinical trials

    ClinicalTrials.gov record NCT06217562↗

    PeptideScanner retained ClinicalTrials.gov record NCT06217562 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  18. Literature metadata

    Acquired transient vasopressin deficiency by cannabinoids and other substances.↗

    PubMed lists PMID 41668460 in Endocrinology as Journal Article, Review, with publication-date metadata of 2026-03-06 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  19. Regulatory

    Federal Register notice 2026-13492↗

    The Federal Register published notice 2026-13492, attributed to FDA and its parent HHS department, on 2026-07-06. Its official title is “Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

  20. Literature metadata

    Pediatric Central Diabetes Insipidus due to Arginine Vasopressin Deficiency in the Perianesthetic Period.↗

    PubMed lists PMID 41552892 in Paediatric anaesthesia as Journal Article, Review, with publication-date metadata of 2026-01-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  21. Literature metadata

    Role of oxytocin and vasopressin in alcohol use disorder.↗

    PubMed lists PMID 39523056 in International review of neurobiology as Journal Article, Review, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural, with publication-date metadata of 2024-10-08 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  22. Clinical trials

    ClinicalTrials.gov record NCT04592744↗

    PeptideScanner retained ClinicalTrials.gov record NCT04592744 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  23. Regulatory

    Federal Register notice 2026-11062↗

    The Federal Register published notice 2026-11062, attributed to FDA and its parent HHS department, on 2026-06-03. Its official title is “Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

  24. Clinical trials

    ClinicalTrials.gov record NCT07614438↗

    PeptideScanner retained ClinicalTrials.gov record NCT07614438 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  25. Regulatory

    Drugs@FDA application ANDA212068↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212068 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.↗

  26. Regulatory

    Drugs@FDA application ANDA212069↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212069 with status AP dated 2026-05-06, and names vasopressin among the application record's active ingredients.↗

  27. Literature metadata

    Vasopressin and steroids in addition to adrenaline in cardiac arrest (VAST-A) - A randomised pilot study.↗

    PubMed lists PMID 40154876 in Resuscitation as Journal Article, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-03-26 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  28. Clinical trials

    ClinicalTrials.gov record NCT05738148↗

    PeptideScanner retained ClinicalTrials.gov record NCT05738148 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-04-09, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  29. Literature metadata

    Plasma concentrations of peptide hormones: Unrealistic levels of vasopressin (AVP), oxytocin (OXT), and brain natriuretic peptide (BNP).↗

    PubMed lists PMID 39034759 in Acta physiologica (Oxford, England) as Journal Article, Review, with publication-date metadata of 2024-07-22 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  30. Clinical trials

    ClinicalTrials.gov record NCT02118467↗

    PeptideScanner retained ClinicalTrials.gov record NCT02118467 at 2026-11-15T22:08:31.832Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  31. Literature metadata

    Arginine Vasopressin (AVP) Deficiency: Diagnosis and Treatment - An Update.↗

    PubMed lists PMID 41497289 in Indian journal of endocrinology and metabolism as Journal Article, Review, with publication-date metadata of 2025-12-19 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  32. Literature metadata

    Copeptin as a Marker for Vasopressin Dysregulation and Diagnosis.↗

    PubMed lists PMID 41070791 in The journal of applied laboratory medicine as Journal Article, Review, with publication-date metadata of 2026-01-05 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2025

12 records
  1. Literature metadata

    Arginine vasopressin deficiency after surgical ligation of an unruptured anterior communicating artery aneurysm - a case report and literature review.↗

    PubMed lists PMID 41341140 in Frontiers in endocrinology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05568160↗

    PeptideScanner retained ClinicalTrials.gov record NCT05568160 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-12-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  3. Literature metadata

    Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?↗

    PubMed lists PMID 40731360 in Critical care (London, England) as Journal Article, Review, with publication-date metadata of 2025-07-29 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Vasopressin in traumatic hemorrhagic shock.↗

    PubMed lists PMID 39936940 in Current opinion in anaesthesiology as Journal Article, Systematic Review, with publication-date metadata of 2025-01-20 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Evidence for the contribution of vasopressin V1B receptors in the pathophysiology of depression.↗

    PubMed lists PMID 39608503 in Biochemical pharmacology as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-11-26 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Aptamers and MIPs as alternative molecular recognition elements for vasopressin and oxytocin sensing: A review.↗

    PubMed lists PMID 40023907 in Biosensors & bioelectronics as Journal Article, Review, with publication-date metadata of 2025-02-23 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT06547892↗

    PeptideScanner retained ClinicalTrials.gov record NCT06547892 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-04-13, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  8. Literature metadata

    Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine.↗

    PubMed lists PMID 40160705 in Frontiers in veterinary science as Journal Article, Review, with publication-date metadata of 2025-03-14 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT05506319↗

    PeptideScanner retained ClinicalTrials.gov record NCT05506319 at 2026-11-15T22:08:31.832Z. Its registry update date was 2025-03-14, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  10. Literature metadata

    Hyponatremia due to preserved non-osmotic arginine vasopressin secretion in adipsic diabetes insipidus: a case report with review of literature.↗

    PubMed lists PMID 39111874 in Endocrine journal as Case Reports, Journal Article, Review, with publication-date metadata of 2024-08-07 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Hemodynamic Management with Vasopressin for Cardiovascular Surgery.↗

    PubMed lists PMID 39768943 in Medicina (Kaunas, Lithuania) as Journal Article, Review, with publication-date metadata of 2024-12-16 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    [Revisiting the vasopressin V2 receptor].↗

    PubMed lists PMID 39780566 in Sheng li xue bao : [Acta physiologica Sinica] as Journal Article, Review, English Abstract, with publication-date metadata of 2024-12-25 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

6 records
  1. Literature metadata

    The Role of Oxytocin and Vasopressin in People with Borderline Personality Disorder: A Closer Look at Adolescents.↗

    PubMed lists PMID 39596113 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2024-11-09 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02975999↗

    PeptideScanner retained ClinicalTrials.gov record NCT02975999 at 2026-11-15T22:08:31.832Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  3. Literature metadata

    Arginine vasopressin deficiency onset after COVID-19 vaccination with positive anti-rabphilin-3A antibodies: a case report and literature review.↗

    PubMed lists PMID 39107738 in BMC endocrine disorders as Case Reports, Journal Article, Review, with publication-date metadata of 2024-08-06 (day precision). PeptideScanner associated the retained record with the identity slug vasopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Regulatory

    Drugs@FDA application NDA217766↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 217766 with status AP dated 2024-07-11, and names vasopressin among the application record's active ingredients.↗

  5. Regulatory

    Drugs@FDA application ANDA213988↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213988 with status AP dated 2024-05-08, and names vasopressin among the application record's active ingredients.↗

  6. Regulatory

    Drugs@FDA application ANDA216963↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 216963 with status AP dated 2024-02-09, and names vasopressin among the application record's active ingredients.↗

Source year

2023

3 records
  1. Regulatory

    Drugs@FDA application ANDA217987↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 217987 with status AP dated 2023-12-06, and names vasopressin among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application NDA217569↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 217569 with status AP dated 2023-09-29, and names vasopressin among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA213206↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 213206 with status AP dated 2023-05-26, and names vasopressin among the application record's active ingredients.↗

Source year

2022

3 records
  1. Regulatory

    Drugs@FDA application ANDA214314↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 214314 with status AP dated 2022-08-15, and names vasopressin among the application record's active ingredients.↗

  2. Regulatory

    Drugs@FDA application ANDA212944↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 212944 with status AP dated 2022-08-05, and names vasopressin among the application record's active ingredients.↗

  3. Regulatory

    Drugs@FDA application ANDA211857↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211857 with status AP dated 2022-07-18, and names vasopressin among the application record's active ingredients.↗

Source year

2021

1 record
  1. Regulatory

    Drugs@FDA application ANDA211538↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 211538 with status AP dated 2021-12-15, and names vasopressin among the application record's active ingredients.↗

Source year

2020

3 records
  1. Regulatory

    Federal Register notice 2020-26133↗

    The Federal Register published notice 2020-26133, attributed to FDA and its parent HHS department, on 2020-11-25. Its official title is “Termination of the Food and Drug Administration's Unapproved Drugs Initiative; Request for Information Regarding Drugs Potentially Generally Recognized as Safe and Effective,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

  2. Regulatory

    Drugs@FDA application NDA212593↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 212593 with status AP dated 2020-08-03, and names vasopressin among the application record's active ingredients.↗

  3. Regulatory

    Federal Register notice 2020-16649↗

    The Federal Register published notice 2020-16649, attributed to FDA and its parent HHS department, on 2020-07-31. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

Source year

2019

9 records
  1. Clinical trials

    ClinicalTrials.gov record NCT01093768↗

    PeptideScanner retained ClinicalTrials.gov record NCT01093768 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-12-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00628550↗

    PeptideScanner retained ClinicalTrials.gov record NCT00628550 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-09-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  3. Regulatory

    Federal Register notice 2019-18932↗

    The Federal Register published notice 2019-18932, attributed to FDA and its parent HHS department, on 2019-09-03. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01962870↗

    PeptideScanner retained ClinicalTrials.gov record NCT01962870 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-05-24, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01611935↗

    PeptideScanner retained ClinicalTrials.gov record NCT01611935 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-05-21, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT03930069↗

    PeptideScanner retained ClinicalTrials.gov record NCT03930069 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-04-29, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT01800877↗

    PeptideScanner retained ClinicalTrials.gov record NCT01800877 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-03-12, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  8. Regulatory

    Federal Register notice 2019-03810↗

    The Federal Register published notice 2019-03810, attributed to FDA and its parent HHS department, on 2019-03-04. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT01318278↗

    PeptideScanner retained ClinicalTrials.gov record NCT01318278 at 2026-11-15T22:08:31.832Z. Its registry update date was 2019-02-20, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

2018

4 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00886262↗

    PeptideScanner retained ClinicalTrials.gov record NCT00886262 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-10-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  2. Regulatory

    Federal Register notice 2018-18614↗

    The Federal Register published notice 2018-18614, attributed to FDA and its parent HHS department, on 2018-08-28. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT01718613↗

    PeptideScanner retained ClinicalTrials.gov record NCT01718613 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-05-18, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT01393704↗

    PeptideScanner retained ClinicalTrials.gov record NCT01393704 at 2026-11-15T22:08:31.832Z. Its registry update date was 2018-02-15, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

2017

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT02223429↗

    PeptideScanner retained ClinicalTrials.gov record NCT02223429 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-06-05, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT00358579↗

    PeptideScanner retained ClinicalTrials.gov record NCT00358579 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-03-17, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

2016

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT01861015↗

    PeptideScanner retained ClinicalTrials.gov record NCT01861015 at 2026-11-15T22:08:31.832Z. Its registry update date was 2016-01-22, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

2015

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00748072↗

    PeptideScanner retained ClinicalTrials.gov record NCT00748072 at 2026-11-15T22:08:31.832Z. Its registry update date was 2015-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

2014

2 records
  1. Clinical trials

    ClinicalTrials.gov record NCT00379522↗

    PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.↗

  2. Regulatory

    Drugs@FDA application NDA204485↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 204485 with status AP dated 2014-04-17, and names vasopressin among the application record's active ingredients.↗

Source year

2013

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT01700478↗

    PeptideScanner retained ClinicalTrials.gov record NCT01700478 at 2026-11-15T22:08:31.832Z. Its registry update date was 2013-02-11, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

2012

1 record
  1. Regulatory

    Federal Register notice 2012-12040↗

    The Federal Register published notice 2012-12040, attributed to FDA and its parent HHS department, on 2012-05-18. Its official title is “Determination That PITRESSIN TANNATE IN OIL (Vasopressin Tannate) Injection, 5 Pressor Units/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗

Source year

2006

1 record
  1. Clinical trials

    ClinicalTrials.gov record NCT00269685↗

    PeptideScanner retained ClinicalTrials.gov record NCT00269685 at 2026-11-15T22:08:31.832Z. Its registry update date was 2006-05-29, and PeptideScanner's reviewed identity mapping was vasopressin.↗

Source year

1998

1 record
  1. Regulatory

    Federal Register notice 98-25713↗

    The Federal Register published notice 98-25713, attributed to FDA and its parent HHS department, on 1998-09-25. Its official title is “Parke-Davis Pharmaceutical Research et al.; Withdrawal of Approval of 14 New Drug Applications and 13 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.↗